Global Drug Pricing Reforms and Their Commercial Fallout: A Legal Perspective On MFN and India-U.S. Pharma Trade

The U.S government revived the “Most Favoured Nation” i.e the MFN drug pricing policy in May 2025, aimed at curbing exorbitant medicine costs by tying U.S. drug prices to the lowest rates paid by developed nations. The move not only has rooted in trade law principles but has also sent ripples through the pharmaceutical world- […]